Plus Therapeutics (PSTV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Voting matters and shareholder proposals
Election of six directors for a one-year term, with nominees listed for shareholder approval.
Ratification of CBIZ P.C. as the independent registered public accounting firm for the 2026 fiscal year.
Advisory vote on executive compensation for named executive officers.
Approval of the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan.
Additional business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Six director nominees are presented for election, each to serve until the 2027 annual meeting or until a successor is elected.
Executive compensation and say-on-pay
Shareholders are asked to provide a non-binding advisory vote on the compensation of named executive officers.
Proposal includes approval of amendments to the 2020 Stock Incentive Plan.
Latest events from Plus Therapeutics
- Net loss narrowed, cash and investments rose, and funding remains critical amid clinical and commercial progress.PSTV
Q1 202615 May 2026 - All proposals, including board election and stock plan amendment, were approved by shareholders.PSTV
AGM 202614 May 2026 - Board seeks approval for director elections, auditor ratification, and expanded equity plan.PSTV
Proxy filing31 Mar 2026 - Expanded CNSide coverage and REYOBIQ clinical progress drove 2025, with a $22.4M net loss.PSTV
Q4 202513 Mar 2026 - Positive clinical data, new grants, and CNSide launch offset by financial and regulatory risks.PSTV
Q2 20241 Feb 2026 - $15M raise funds clinical trials, CNSide growth, and 2026 expansion with strong payor coverage.PSTV
Business update22 Jan 2026 - Promising CNS radiotherapeutic programs advance toward pivotal trials and commercial diagnostics.PSTV
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Clinical progress and new financing support growth, but liquidity and compliance risks remain.PSTV
Q3 202414 Jan 2026 - IPO seeks to fund CNS cancer radiotherapeutics and diagnostics amid ongoing financial risk.PSTV
Registration Filing9 Jan 2026